Cédric Coulouarn, Institut National de la Sante et de la Recherche Medicale (Inserm), Université de Rennes 1, Rennes F-35000, France
Author contributions: Coulouarn C solely contributed to this paper.
Supported by Inserm, Université de Rennes 1, Ligue Contre le Cancer, No. CD22, No. CD35, and No. CD85; INCa, and ITMO Cancer AVIESAN (Alliance Nationale pour les Sciences de la Vie et de la Santé) dans le cadre du Plan cancer (Non-coding RNA in cancerology: fundamental to translational), No. C18007NS.
Conflict-of-interest statement: No conflict-of-interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Cédric Coulouarn, PhD, Senior Researcher, Principal Investigator, Team Leader, Institut National de la Sante et de la Recherche Medicale (Inserm), Université de Rennes 1, CHU Pontchaillou, 2 rue Henri Le Guilloux, Rennes F-35033, France. email@example.com
Received: May 20, 2020
Peer-review started: May 20, 2020
First decision: June 4, 2020
Revised: June 9, 2020
Accepted: June 12, 2020
Article in press: June 12, 2020
Published online: June 28, 2020